News
2011 | 2010 | 2009 | 2008 | 2007 | 2006
London, 3 November2011
ImmuPharma’s Lupuzor™ granted approval to start phase III and Fast Track designation by the FDA
ImmuPharma plc (LSE:IMM) (“Immupharma” or the “Company” or the “Group”), the specialist discovery and development pharmaceutical company is pleased to provide an update on the development status of its Lupus drug candidate Lupuzor™.
London, 21 October 2011
ImmuPharma regains Lupuzor rights from Cephalon due to Teva merger
ImmuPharma plc (LSE:IMM) ("Immupharma" or the "Company" or the "Group"), the specialist discovery and development pharmaceutical company is pleased to announce that following discussions with Cephalon Inc (Cephalon), its licensee for Lupuzor™, it has regained rights to Lupuzor™, due to the acquisition of Cephalon by Teva Pharmaceutical Industries Ltd (Teva).
London, 30 September 2011
INTERIM RESULTS ANNOUNCEMENT
For the six months ended 30 June 2011
ImmuPharma plc (LSE:IMM) ("Immupharma" or the "Company" or the "Group"), the specialist discovery and development pharmaceutical company is pleased to announce its interim results for the six months ended 30 June 2011.
London, 23 September 2011
Notification of Interim Results Date: 30 September 2011
ImmuPharma PLC (AIM:IMM), the specialist discovery and development pharmaceutical company, is scheduled to announce its Interim Results for the six months ended 30 June 2011 on 30 September 2011.
London, 12 July 2011
Notification of Major Interest in Shares
London, 19 May 2011
Result of Annual General Meeting
ImmuPharma PLC (AIM:IMM), the specialist drug discovery and development company, held its AGM earlier today and is pleased to announce that all resolutions were duly passed.
London, 05 May 2011
Cancer Compound IPP-204106 paper published
in prestigious medical journal
ImmuPharma plc (LSE:IMM) ("Immupharma" or the "Company" or the "Group"), the specialist discovery and development pharmaceutical company is pleased to announce the publication of a scientific paper on its cancer compound IPP-204106 in Cancer Research, a prestigious medical journal of the American Association for Cancer Research.
London, 26 April 2011
Annual Report and Accounts
Notice of Annual General Meeting: 19 May 2011
In accordance with Rule 20 of the AIM Rules, ImmuPharma PLC (AIM:IMM), the specialist drug discovery and development company, confirms that the Annual Report and Accounts for the year ended 31 December 2010, has been posted to shareholders.
London, 5 April 2011
PRELIMINARY RESULTS ANNOUNCEMENT
for the year ended 31 December
2010
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company is pleased to announce its preliminary audited results for the year ended 31 December 2010.
London, 21 February 2011
Update on progress of Phase I/IIa Clinical Trial with IPP-204106: Cancer patients stabilised with ImmuPharma's Cancer Compound
ImmuPharma plc (LSE:IMM) ("Immupharma" or the "Company"or the "Group"), the specialist discovery and development pharmaceutical company is pleased to announce encouraging results from its ongoing phase I/IIa clinical trial in cancer patients.
Key Highlights:
Around half of the cancer patients that have undergone treatment with ImmuPharma's drug candidate IPP-204106 are in stable condition (their disease has stopped progressing) without any other drug treatment. All the patients that enrolled in the study were suffering from advanced cancer with metastases and had all failed their previous treatments with other existing cancer drugs.
London, 19 October 2010
Update on Phase IIa Clinical Trial with
Cancer Compound IPP-204106
London, 11 October 2010
ADDITIONAL LISTING AND TOTAL VOTING RIGHTS
PICTET INCREASE HOLDING TO OVER 3%
London, 30 September 2010
INTERIM RESULTS ANNOUNCEMENT
for the six months ended 30 June 2010
ImmuPharma plc (LSE:IMM) ("Immupharma" or the "Company" or the "Group"), the specialist discovery and development pharmaceutical company is pleased to announce its interim results for the six months ended 30 June 2010.
INTERIM HIGHLIGHTS
-
First patients dosed with IPP-204106, ImmuPharma's anti-cancer compound with a novel and promising mechanism of action, in a Phase IIa cancer trial, after receipt of an Investigational New Drug (IND) approval from AFSSAPS, Agence Francaise de Securite Sanitaire des Produits de Sante.
-
Cephalon, Inc (Cephalon), ImmuPharma's partner for Rigerimod (LupuzorTM), commenced the recruitment of lupus patients for a Phase IIb trial being conducted largely in the US. This study has been designed to provide US-based investigators and the US FDA with clinical data obtained mainly in the USA. The data generated from this trial will be part of the package to be submitted to the FDA and other regulatory authorities for approval. Positive Phase IIb data from outside the USA has previously been announced.
-
Cephalon has also initiated development of LupuzorTM in Japan through its partner Symbio Pharmaceuticals.
-
ImmuPharma remains committed to its other compounds in R&D.
-
Strong cash position of £20m (as at 30 June 2010).
-
Received Best Drug Development Company in Europe 2010 Award from the New Economy.
-
Basic and diluted loss per share were 0.10p and 0.10p respectively (31 December 2009: basic and diluted earnings per share 10.46p and 9.99p respectively).
London, 28 September 2010
Notification of Interim Results
ImmuPharma PLC (AIM:IMM), the specialist drug discovery and development company, is scheduled to announce its Interim Results for the six months ended 30 June 2010 on Thursday 30th September 2010.
London, 23 June 2010
Cephalon, ImmuPharma license partner for Rigerimod (Lupuzor)
initiates critical steps in its development program
US Recruitment commences
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to announce today that Cephalon Inc., its license partner for IPP-201101 (Rigerimod; Lupuzor) has started the recruitment of lupus patients for a Phase IIb trial in the US. This study was designed to allow US based investigators and the FDA to evaluate Rigerimod (Lupuzor) as a treatment for lupus before commencing a Phase III clinical trial. A large number of centres are involved and the study is expected to be extended to EU sites within a few months. The data generated from this trial will be part of the package to be submitted to the FDA and other regulatory authorities for approval.
London, 17 June 2010
Result of Annual General Meeting
ImmuPharma PLC (AIM:IMM), the specialist drug discovery and development company, held its AGM earlier today and is pleased to announce that all resolutions were duly passed.
London, 10 June 2010
Annual Report and Accounts
Notice of Annual General Meeting : 17 June 2010
In accordance with Rule 20 of the AIM Rules, ImmuPharma PLC (AIM:IMM), the specialist drug discovery and development company, confirms that the Annual Report and Accounts for the year ended 31 December 2009, has been posted to shareholders.
London, 19 May 2010
ImmuPharma receives approval for
Initiation of PhaseI/IIA Studies in Cancer
ImmuPharma plc (LSE:IMM), the specialist drug discovery and development company, is pleased to announce that it received an Investigational New Drug (IND) approval from AFSSAPS, Agence Francaise de Securite Sanitaire des Produits de Sante, for a Phase I/IIa study in patients of IPP-204106, its anti-cancer compound with a novel and promising mechanism of action. The first patients are expected to be dosed within the next few weeks.
London, 19 May 2010
PRELIMINARY RESULTS ANNOUNCEMENT
for the year ended 31 December 2009
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to announce its preliminary audited results for the year ended 31 December 2009.
Key Highlights:
Revenue reported of £22 million for the period following the receipt of $30 million from Cephalon, Inc. as a license payment for LupuzorTM in February, 2009
Basic and diluted earnings per share were 10.46p and 9.99p respectively (31 December 2008: 6.23p and 6.07p respectively)
Strong cash position of £22.5 million. Cash balance resulting from LupuzorTM agreement to be used to develop the other promising compounds in the pipeline
Lead candidate for the treatment of Lupus, LupuzorTM, licensed to Cephalon, Inc in a transaction worth up to $500m in milestone payments in addition to significant royalties. $45m in cash received to date - $15m in Q4 2008 and $30m in Q1 2009
Final results of the Phase IIb study of LupuzorTM showed a clinically significant improvement in patient response rate versus placebo
Received IND approval from AFSSAPS, Agence Francaise de Securite Sanitaire des Produits de Sante, for a Phase I/IIa study in patients, IPP-204106, our anti-cancer compound with a novel and promising mechanism of action. First patients expected to be dosed within the next few weeks
Received numerous awards during the year, including: 'Breakthrough of the Year 2009' European Mediscience Award, 'Best Technology 2009' AIM Award and 'Best Drug Development Company Europe 2010' New Economy Award.
London, 8 April 2010
Best Drug Development Company in Europe Award
ImmuPharma plc (LSE:IMM), the specialist discovery and development pharmaceutical company, has been voted "Best Drug Development Company, Europe" at The New Economy Pharmaceutical & Healthcare Awards 2010.
This award follows on from two notable wins in 2009 namely; "Best Technology Award" at the AIM Awards, organized by the London Stock Exchange and "Breakthrough of the year 2009" at the European Mediscience Awards.
London, 5 January 2010
Additional Listing and Total Voting Rights
Following the receipt of a notice of exercise of options, application has been made to the London Stock Exchange for the admission of 365,000 new ordinary shares to trading on AIM. The admission of the new ordinary shares will become effective today. The new ordinary shares rank pari passu with the existing ordinary shares of the Company.
London, 5 January 2010
ING take 4% stake in ImmuPharma plc
ImmuPharma plc (LSE:IMM), the specialist discovery and development pharmaceutical company is pleased to announce that ING, Belgium (ING) has taken a 4% stake in the company with the exercise of warrants issued in December 2006. These warrants were exercised on 24 December 2009.
